Silver Book Fact

Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient– a glaucoma treatment that delays the disease progression could significantly reduce its economic burden.

Lee P, Walt J, Doyle J, Kotak S, et al. A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma. Archives of Ophthalmology. 2006; 124(1): 12-9. http://archopht.ama-assn.org/cgi/content/abstract/124/1/12

Reference

Title
A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma
Publication
Archives of Ophthalmology
Publication Date
2006
Authors
Lee P, Walt J, Doyle J, Kotak S, et al.
Volume & Issue
Volume 124, Issue 1
Pages
12-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Laser Treatment for DR
    Laser treatment of PDR can reduce the 5-year risk of blindness by 90%, and the risk of visual loss from DME by 50%.  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • Of the 8 Million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years.  However the NEI-sponsored Age-Related Eye…  
  • Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients…  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.